Mesoblast (Mesoblast) Debt-to-Asset : 0.18 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Debt-to-Asset?

Mesoblast's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.39 Mil. Mesoblast's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $110.61 Mil. Mesoblast's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $670.29 Mil. Mesoblast's debt to asset for the quarter that ended in Dec. 2023 was 0.18.

Mesoblast Debt-to-Asset Historical Data

The historical data trend for Mesoblast's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Debt-to-Asset Chart

Mesoblast Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Asset

Get a 7-Day Free Trial

0.13

0.14

0.16

0.17

Mesoblast Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.17	0.18	0.17	-	0.18

Competitive Comparison of Mesoblast's Debt-to-Asset

For the Biotechnology subindustry, Mesoblast's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Mesoblast's Debt-to-Asset falls into.

Mesoblast Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Mesoblast's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(10.012	+	106.483)	/	669.415
	=	0.17

Mesoblast's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(11.385	+	110.614)	/	670.285
	=	0.18

Mesoblast (NAS:MESO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Mesoblast Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Mesoblast's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast (Mesoblast) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

MEOBF:USA LWB:Germany MSB:Australia

Address

Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.